Bottom line
Is RYHCX a good fund? The bottom line
RYHCX is the Class C share class of Health Care Fund, an actively managed health care sector mutual fund from Guggenheim.
It charges 2.4% — about $240 a year on every $10,000 invested, more expensive than 98% of health care sector funds we track.
It returned +12.3% over one year, +4.1% a year over five years, +6.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $19.4 million in net assets and 135 holdings, its largest position is Eli Lilly & Company (3.6%) and the top 10 make up 20.6% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 79% top-holdings overlap).
What stands out
- No front-end sales load
What to watch
- Expensive for its category (2.4%)
- 12b-1 marketing fee of 1% a year
- Small fund ($19.4 million) — small funds are likelier to close
- High turnover (244% a year) can mean more taxable distributions
Updated Nov 19, 2026
What RYHCX invests in
The Health Care Fund (the Fund) seeks to provide capital appreciation by investing in companies that are involved in the health care industry (Health Care Companies).
Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Advisor employs a proprietary quantitative and qualitative methodology to identify Health Care Companies in which to invest. The methodology utilizes screens based on price, liquidity, and tradability. The securities are then weighted using a proprietary modified capitalization weighting methodology. The portfolio may be further adjusted to comply with regulatory investment limitations or as determined appropriate by the Advisor. The Fund may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. Health Care…
From the fund's prospectus (filed Jul 29, 2026).
RYHCX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RYHCX | +12.3% | +4.1% | +6.8% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What RYHCX costs
On a $10,000 investment, RYHCX's 2.4% expense ratio costs about $240 a year. The prospectus estimates $2,782 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
RYHCX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Company LLY | 3.63% |
| 2 | Johnson & Johnson JNJ | 2.88% |
| 3 | Abbvie Inc ABBV | 2.52% |
| 4 | Unitedhealth Group Inc UNH | 2.22% |
| 5 | Merck & Company Inc MRK | 2.04% |
| 6 | Thermo Fisher Scientific Inc TMO | 1.61% |
| 7 | Amgen Inc AMGN | 1.56% |
| 8 | Abbott Laboratories ABT | 1.42% |
| 9 | Gilead Sciences Inc GILD | 1.39% |
| 10 | Vertex Pharmaceuticals Inc VRTX | 1.34% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 20.6% of the fund. See all top 25 holdings and asset mix →
Alternatives to RYHCX
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 79% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 80% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 81% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 76% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 64% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 66% | Compare |